Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes

R. T. Swords; J. Watts; H. P. Erba; J. K. Altman; M. Maris; F. Anwer; Z. Hua; H. Stein; H. Faessel; F. Sedarati; B. J. Dezube; F. J. Giles; B. C. Medeiros; D. J. DeAngelo

doi:10.1038/bcj.2017.1

Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes

R. T. Swords, J. Watts, H. P. Erba, J. K. Altman, M. Maris, F. Anwer, Z. Hua, H. Stein, H. Faessel, F. Sedarati, B. J. Dezube, F. J. Giles, B. C. Medeiros, D. J. DeAngelo

Medicine

Research output: Contribution to journal › Letter › peer-review

32 Scopus citations

Original language	English (US)
Article number	e520
Journal	Blood Cancer Journal
Volume	7
Issue number	2
DOIs	https://doi.org/10.1038/bcj.2017.1
State	Published - Feb 3 2017

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1038/bcj.2017.1

Cite this

Swords, R. T., Watts, J., Erba, H. P., Altman, J. K., Maris, M., Anwer, F., Hua, Z., Stein, H., Faessel, H., Sedarati, F., Dezube, B. J., Giles, F. J., Medeiros, B. C., & DeAngelo, D. J. (2017). Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes. Blood Cancer Journal, 7(2), Article e520. https://doi.org/10.1038/bcj.2017.1

Swords, RT, Watts, J, Erba, HP, Altman, JK, Maris, M, Anwer, F, Hua, Z, Stein, H, Faessel, H, Sedarati, F, Dezube, BJ, Giles, FJ, Medeiros, BC & DeAngelo, DJ 2017, 'Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes', Blood Cancer Journal, vol. 7, no. 2, e520. https://doi.org/10.1038/bcj.2017.1

@article{15b02fa2bd654ba1ad249c71a4617350,

title = "Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes",

author = "Swords, {R. T.} and J. Watts and Erba, {H. P.} and Altman, {J. K.} and M. Maris and F. Anwer and Z. Hua and H. Stein and H. Faessel and F. Sedarati and Dezube, {B. J.} and Giles, {F. J.} and Medeiros, {B. C.} and DeAngelo, {D. J.}",

note = "Funding Information: This research was supported by Takeda Pharmaceuticals, Inc. This study is registered with ClinicalTrials.gov, number NCT00677170. RTS received support from grant NIH 1KL2TR000461.",

year = "2017",

month = feb,

day = "3",

doi = "10.1038/bcj.2017.1",

language = "English (US)",

volume = "7",

journal = "Blood Cancer Journal",

issn = "2044-5385",

publisher = "Nature Publishing Group",

number = "2",

}

TY - JOUR

T1 - Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes

AU - Swords, R. T.

AU - Watts, J.

AU - Erba, H. P.

AU - Altman, J. K.

AU - Maris, M.

AU - Anwer, F.

AU - Hua, Z.

AU - Stein, H.

AU - Faessel, H.

AU - Sedarati, F.

AU - Dezube, B. J.

AU - Giles, F. J.

AU - Medeiros, B. C.

AU - DeAngelo, D. J.

N1 - Funding Information: This research was supported by Takeda Pharmaceuticals, Inc. This study is registered with ClinicalTrials.gov, number NCT00677170. RTS received support from grant NIH 1KL2TR000461.

PY - 2017/2/3

Y1 - 2017/2/3

UR - http://www.scopus.com/inward/record.url?scp=85011556228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011556228&partnerID=8YFLogxK

U2 - 10.1038/bcj.2017.1

DO - 10.1038/bcj.2017.1

M3 - Letter

C2 - 28157218

AN - SCOPUS:85011556228

SN - 2044-5385

VL - 7

JO - Blood Cancer Journal

JF - Blood Cancer Journal

IS - 2

M1 - e520

ER -

Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this